You know that little portable DVD player you have for the car. The same one that sits on the back of the seat of that jet you flew on? The same one you use at home to keep the kids quiet in their bedroom when you have guests over?
Well it’s dead.
And its killer isn’t a cheaper version. [...]

[Read more →]

Alzheimers is a very real and human tragedy that robs people not only of their the identify but also their sense of purpose and place in the world. Dealing with Alzheimers patients is even more difficult.
One of the recurring issues with Alzheimers patients is the development of episodes where the patient has a sudden and urgent need ‘to get home’. [...]

[Read more →]

Cogentum client Acrux today announced one of the biggest licensing  deals in Australian Biotech history. The deal with Eli Lilly ranks up there as one of the biggest outcomes for an Australian biotech. From the announcements you will see that this is a superb result for any Australian company seeking to license it’s technology.

Cogentum worked [...]

[Read more →]

Have you ever wondered how easy it would be if you could pay with your credit card anywhere, at any time?
Hmmm, nice idea, but the problem has always been a lack of terminals. After all, not many garage sales have their own EFTPOS terminal, right?
WRONG! Silicon Valley based start up firm Square have busted this [...]

[Read more →]

When I am really sick, I see a Doctor. Why? Because they are trained to assess the symptoms/data/evidence I present with. In essence I trust that they know what they are doing.
This trust is based on my understanding that through a unique and powerful combination of training, education and experience they are able to assess the data and from [...]

[Read more →]

One of the leading academics and authors on Business and Management Dr Henry Minztberg has written a thought provoking piece in the MIT Sloan Management Review on whether the executive bonus schemes should stay or be scrapped.
Mintzberg says, “Executive bonuses—especially in the form of stock and option grants—represent the most prominent form of legal corruption that has been [...]

[Read more →]

For the last 8 months we have been working with Neopec, a new company that is commercialising a revolutionary approach to breast reconstruction using technology developed at Melbourne, Australia’s Bernard O’Brien Institute of Microsurgery and the Australian Tissue Engineering Center.
Neopec will allow women who have been through the trauma of breast cancer and mastectomy to re-grow [...]

[Read more →]

Great news is continuing to emerge from the Australian biotech sctor.
We are glad to see that one of our clients, Acrux, is leading the charge as it continues to build a cogent story for its investors and the market.
Equally pleasing is the rapid progress of Universal Biosensors (sadly, not a client!). This company is, in our [...]

[Read more →]

Web3.0 has arrived

[Read more →]

The following piece appeared in September 28th edition of Bioshares #330, Australia’s leading analysis and commentary on the Biotech sector. It summarises our out take on the 2009 Bioshares conference held at Thredbo in September.

Don’t worry about your Technology, show me the Strategy

The 2009 Thredbo summit graphically illustrated why strategy is becoming increasingly more valuable [...]

[Read more →]